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ABSTRACT
Many food-derived peptides with antihypertensive 
activity have been reported. However, a reduced number of 
studies have been conducted to prove in vivo the efficacy of 
most of the currently reported antihypertensive peptides. 
Thus, just a few of these bioactive peptides are utilized as 
supplements or ingredients for functional foods production. 
In addition to in vivo evaluations, another challenging task 
is the delivery of bioactive peptides in physiological condi-
tions, but studies about this topic are scarce. Notably, some 
proteins are able to form gels that have different characteris-
tics related to the pH of the environment. Bioactive peptides 
can be entrapped into such gels structure and be released 
in different physiological environments (e. g. low pH in the 
stomach and neutral in the intestine). Thus, the selection of 
macronutrients could play a critical role in the design of food 
matrices intended to be used as containers and releasers of 
antihypertensive peptides.
Keywords: Bioactive compounds; Food matrix; Bioavailabi-
lity.
RESUMEN
Muchos péptidos derivados de los alimentos con acti-
vidad antihipertensiva han sido reportados. Sin embargo, un 
reducido número de estudios han sido conducidos para pro-
bar la eficacia de la mayoría de los péptidos que actualmente 
reportan actividad antihipertensiva. Así, solo unos pocos de 
esos péptidos bioactivos son utilizados como suplementos 
o ingredientes para la producción de alimentos funcionales. 
Además de las evaluaciones in vivo, otra tarea que resulta un 
reto es la liberación péptidos bioactivos en condiciones fisio-
lógicas, pero los estudios sobre este tópico son escasos. No-
tablemente, algunas proteínas son capaces de formar geles 
que tienen diferentes características relacionadas con el pH 
del medio en el que se encuentren. Los péptidos bioactivos 
pueden quedar atrapados en las estructuras de esos geles y 
ser luego liberados en diferentes ambientes fisiológicos (e. 
g. bajo pH en el estómago y neutro en el intestino). Así, la 
selección de macronutrimentos puede jugar un papel crítico 
en el diseño de matrices alimentarias para ser usadas como 
vehículos y liberadores de péptidos antihipertensivos.
Palabras clave: Compuestos bioactivos; Matriz alimentaria; 
Biodisponibilidad.
INTRODUCTION
Many peptides derived from a wide range of food 
proteins (animal and non-animal protein sources) and with 
anti-hypertensive properties have been reported. From this 
large spectrum of peptides, just a few of them have been 
tested in clinical trials. For instance, in the website of the U.S. 
National Institutes of Health only 3 studies can be found en-
tering the key words ‘antihypertensive peptide’ categorized 
as ‘dietary supplement’ and just two involving the dietary 
intervention with peptides into a food matrix (US NIH, 2017). 
Although antihypertensive peptides generally show lower 
antihypertensive activity than synthetic drugs, either in vitro 
or in vivo, they are less likely to accumulate in the body and 
to trigger side effects (Li-Chan, 2015). Thus, many studies 
have been conducted in the last two decades to discover 
new antihypertensive peptides with potential to be used as 
ingredients in functional foods.
Often food-derived antihypertensive peptides are tes-
ted in vitro being the inhibition of the angiotensin-converting 
enzyme (ACE) (EC  3.4.15.1) the most common test (Aluko, 
2015). Certainly, to be physiologically relevant in vivo, the 
peptides should remain unaltered through the gastrointesti-
nal tract and be transported across the intestinal epithelium 
(Figure 1). Finally, they must preserve their bioactivity into 
the blood serum conditions to perform specific physiological 
functions (Norris and FitzGerald, 2013). This is particularly 
relevant when testing functional foods. Since in vivo the 
bioactive compounds must be released from the food matrix 
in sufficient amount to play a significant role in the organism, 
in vitro assays are considered as preliminary studies. In this 
mini-review we have focused on the digestion of proteins 
and absorption of peptides as well as on the role of food 
matrices characteristics in the delivery of antihypertensive 
peptides.
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Sources of antihypertensive peptides
Antihypertensive peptides naturally occurred in 
foods, either from animal or non-animal sources (Table 1). 
Until now, the main animal sources of antihypertensive 
peptides are milk proteins (Hernández-Ledesma et al., 2011; 
Beltrán-Barrientos et al., 2016). In fact, the antihypertensive 
peptides commercially available and often used as nutra-
ceutical ingredients for functional foods are derived from 
cow’s milk casein (Ishida et al., 2011; Martítez-Maqueda et al., 
2012; Cicero et al., 2012). Dziuba and Dziuba, (2014) showed 
five antihypertensive milk-derived products commercially 
available and just two of them were food product as it (sour 
milk and margarine). On the other hand, antihypertensive 
peptides from non-animal sources have been widely studied, 
but in most cases, the antihypertensive capacity of such 
peptides was tested in vitro or in vivo in animal models of 
hypertension (García et al., 2013). Martínez-Maqueda et al., 
(2012) reviewed the different antihypertensive peptides tes-
ted in vivo in murine models and their effects on the systolic 
hypertension. From the total of antihypertensive peptides 
reported in the literature, 47 were derived from milk protein, 
10 from egg protein, 40 peptides from other animal protein 
sources, and 41 peptides were derived from non-animal 
sources (Martínez-Maqueda et al., 2012). Although some 
of the peptides showed antihypertensive potential in vitro, 
even better than those commercially available, there was a 
lack of studies proving their efficacy in human beings. This is 
an important issue that has hampered the use of antihyper-
tensive peptides as nutraceutical ingredients for functional 
foods development.   
Protein and peptides digestion and absorption
The bioactive properties of peptides are linked to their 
amino acid composition and sequence. However, the amino 
acid pattern of food-derived peptides is strongly influenced 
by the specific cleavage of gastrointestinal enzymes and this 
could limit the bioaccesibility of specific peptide sequences 
(Cian et al., 2015). Proteins and peptides digestion start at the 
stomach by the action of pepsin and acidic pH. At this site 
the acidic condition denatures/unfolds proteins increasing 
availability for the attack by gastric pepsin. This enzyme 
preferentially attacks peptide bonds involving hydrophobic 
aromatic amino acids i.e., phenylalanine, tryptophan. The 
resulting polypeptides are subjected to further hydrolysis 
by a set of pancreatic enzymes (trypsin, chymotrypsin, 
elastase, carboxypeptidases) with different peptide bonds 
specificities. This process generates polypeptides and amino 
acids at intestinal level. Further peptide bonds hydrolysis is 
mediated by brush border peptidases resulting in bioacces-
sible peptides (Kohlmeier, 2015). These peptides could beco-
me bioavailable either in an intact form or biotransformed 
into smaller peptides with increased or reduced bioactivity. 
Plasma peptidases further contribute to peptide hydrolysis 
limiting the plasma half-life of the peptides. Thus, to be phy-
siologically relevant when used as nutraceuticals or functio-
nal food ingredients, food-derived bioactive peptides should 
Table 1. Peptides with ACE-I Inhibition activity*. 
Tabla 1. Péptidos con actividad inhibitoria de la Enzima Convertidora de 
Angiotensina.
(ID)  SEQUENCE SOURCE








s(7678)  LKPMN  Dried bonito (katsuwonus pelamis)
(7638)  LTF, (7811)  VWIG  Tuna (Thunnus thynnus)
(7751)  CF, 7751 (EY) Shark (Carcharhinus longimanus)
(7506)  GPL, (7747)  FGASTRGA. Alaskan pollock (Gadus chalcogrammus)
(7569)  LKA, (7573)  RMLGNTPTK, 
(7575)  FQKPKR.









(7574)  VLAQYK Cow’s Beef  (Bos Taurus)
(7640) MNP, (7641) TNP Pig (Sus scrofa ssp)
(7648)  FCF, (7686)  FFGRCVSP, 
(7687)  ERKIKVYL, (7688)  
FGRCVSP, (7689)  NIFYCP.
Ovoalbumin (Gallus gallus 
domesticus)
(7806)  LQKW, (7807) LLF Caprine Milk (Capra aegagrus hircus)
(3374)  PFPE, (3495)  
YIPIQYVLSR, (7801)  VRYL, 
(7800)  FFVAPFPEVFGK, 
(7802)  NMAINPSK, (7803)  IPY, 
(7804)  ALNEINQFY, (7805)  
ALNEINQFYQK, (8357)  RYLG, 
(8358)  RYLGY, (8359)  AYFYPEL.
Bovine Milk (Bos Taurus)
(8386)  RASDPLLSV, 
(8387)  RNDDLNYIQ, (8388)  
LAPSLPGKPKPD, (8380)   
AGTTCLFTPLALPYDYSH, (8390)  
RADHPFL, (8391)  YAEERYPIL, 
(8393)  HLFGPPGKKDPV, (8394)  
VGVIKAVDKKAGGAGKVT, (8395)  
QIGLF.
Egg (Gallus gallus domesticus)
(7560)  FFL, (7681)  DG, (8511)  
FFYY, (8512)  WHP, (8513)  FVP, 







(7646)  GYK, (7680)  QK,  (8492) 
KEDDEEEEQGEEE. Pea (Pisum sativum)
(7814)  MDFLI, (7815)  MFDL. Chickpea (Cicer arietinum)
(7819)  IAP, (7820)  GPP, 
(8413)  IPALLKR, (8414)  
AQQLAAQLPAMCR, (8493)  
NPPSV.
Wheat (Triticum spp)
(7821)  RIY Rapeseed (Brassica napus)
(8360)  LTPTSN,  (8361)  
LVVDGEGY, (8364)  LLPSY. Olive seeds (Olea europaea)
(7558)  VK Buckwheat (Fagopyrum esculentum)
(8415)  VNP, (8420)  VWP. Rice (Oryza sativa)





(7744)  GAAELPCSADWW Bullfrog (Rana catesbeiana) 
(3483) GKKIATYQER Yeast (Saccharomyces cerevisiae)
(3486)  VW Sake (Oryza sativa)
(7554)  GEP Tricholoma giganteum (Macrocybe gigantea)
(3486)  VW Sake (Oryza sativa)
(7649)  LRY, (7822)  IAPG, (7823)  
FAL. Algae spp
(7682)  NY Garlic (Allium sativum)
(7651)  YKY Wakame (Undaria pinnatifida)
(7556)  YPLDL Spinach (Spinacia oleracea)
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be digestion resistant or delivered in their bioactive form at 
specific sites of the gastrointestinal tract (Figure 1).
Peptide transport, across the small intestine, can be 
mediated by different mechanisms. Small hydrophilic com-
pounds could permeate the intestinal mucosa through the 
paracellular route. Neutral and positively charged di- and 
tri-peptides are preferentially permeated trough this route. 
Longer peptides i.e., six amino acids length (MW around 
620), are less efficiently permeated and this is independent 
of their net charge (Pauletti et al., 1997). The transcellular 
route is also size dependent, but it is more likely to permeate 
hydrophobic peptides in part due to the lipophilic nature of 
cell membranes (Wada and Lönerdal, 2014). The molecular 
weight cut-off of this passive diffusion pathway of peptides 
using the Caco-2 cell permeability system is estimated at MW 
700 allowing the permeation of peptidic compounds such as 
the renin inhibitor remikiren and the HIV inhibitor saquinavir 
(MW > 600) (Camenisch et al., 1998). On the other hand, the 
transmembrane protein called peptide transporter 1 (PepT1), 
which is located in the brush border, can transport di- and 
tri-peptides into the enterocyte. This mechanism is thought 
to be independent of the peptides net charge and lypophilic 
or hydrophilic properties (Freeman, 2015). Overall, peptide 
length (size) seems more relevant than other physicochemi-
cal properties for peptide transportation through the intes-
tinal mucosa. Thus, after oral or intragastric administration, 
short bioactive peptides (3-5 amino acids length) are the 
ones that reach systemic circulation and show antihyperten-
sive potential. 
In vitro assessment of the bioavailability of bioactive 
peptides usually involves simulated digestion processes 
(gastric and intestinal) and absorption using the Caco-2 
cell line (Ding et al., 2015). Until now, the antihypertensive 
peptides utilized in commercially available food products 
or sold as supplements are digestion resistant and this pro-
perty could increase their bioavailability. Other food-derived 
antihypertensive peptides however could become more 
efficient or be formed after the attack of gastrointestinal 
enzymes. For instance, antihypertensive peptides from some 
ripened cheeses become more efficient after gastrointestinal 
digestion by human gastric or duodenal juices (Qureshi et al., 
2012) and other peptides derived from β-casein have shown 
greater antihypertensive potential after in vitro pancreatic 
digestion (Maeno et al., 1996). Beyond the digestion resistant 
nature of some antihypertensive peptides, food matrices 
could play an important role by either increasing or reducing 
peptides bioaccessibility and/or bioavailability. This is parti-
cularly relevant when these compounds are intended to be 
used as ingredients for functional foods production.
Effect of food matrices characteristics on the bioavailabi-
lity of peptides
A common definition of bioavailability of a nutrient 
is the amount that is absorbed from the diet and used for 
normal body functions (Aggett, 2010). Beyond the concept 
of bioavailability, some other definitions are commonly used 
to describe properties of nutrients. This includes bioconver-
sion (‘fraction of bioavailable nutrient that is converted into 
Mechanical breakdown.
Saliva that homogenizes food 
and helps to pass the 
esophagus
Acidic conditions of the 



















Hydrolysis of proteins and 
peptides.
. Intestine
Figure 1. Physiological barriers for antihypertensive peptides.
Figura 1. Barreras fisiológicas para los péptidos antihipertensivos.
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the active form’), bioefficacy (‘fraction of ingested nutrient 
that has a nutritional effect’), bioaccessibility  (‘fraction that 
is released from food matrix and is available for intestinal 
absorption’) and bioequivalence (Parada and Aguilera, 2007). 
For anti-hypertensive peptides, bioaccessibility and bioavai-
lability are the most used terms.
The bioavailability of peptides could decrease de-
pending on the interaction with macromolecules and/or the 
food matrix. These interactions vary since the magnitude of 
the distance into the structure of the food matrix also varies. 
For instance, the interaction between bioactive molecules 
and macromolecules (e. g. iron-protein hydrogels interac-
tions in rice flours; polyphenol-protein (Moretti et al., 2006; 
Foegeding et al., 2017), in food matrix structures range from 
10 to 100 nanometers (Parada and Aguilera, 2007), while the 
interaction between bioactive compounds and the whole 
food matrix (e. g. phenolic and components of food matrix 
components (Balasundram et al., 2006)) structure is ~100 
micrometers (Parada and Aguilera, 2007). Thus, the design 
of these complexes could be used to both to entrap and to 
release the peptides at physiological level. Since proteins 
have the ability to form stable gels and emulsions at diffe-
rent conditions, they are a good material for controlling the 
release of bioactive compounds. In fact, the physicochemical 
modification of macromolecules could confer them novel 
functions and make them more suitable to develop oral pep-
tide delivery systems (Peppas and Kavimandan, 2006).
Food gels can be considered as three-dimensional 
continuous polymeric networks holding large quantities of 
aqueous solution that shows mechanical rigidity during the 
time (Foegeding, 2006). Gels from proteins have been classi-
fied as globular gels and particulate gels according to their 
stabilization forces and shape at microstructure level. Among 
the globular protein gels, the fine-stranded gels, maintained 
by hydrophobic interactions, are composed by flexible linear 
strands with elastic properties and they resist the rupture for-
ces. On the other hand, particulate gels, stabilized by van der 
Waals forces, are formed by large and spherical aggregates 
which have low elasticity and low rupture resistance (Zuñi-
ga and Troncoso, 2012). According to Norris and Fitzgerald 
(2013), peptide sequences with potential to inhibit ACE have 
commonly limited number of amino acids (2-12) and hydro-
phobic residues at the C-terminal region (e. g. Proline).  This 
last characteristic should be taken into account in the design 
of food matrices intended to contain anti-hypertensive 
peptides with potential to inhibit ACE activity. Thus, due to 
the hydrophobic characteristic of Proline, this amino acid 
will tend to interact with the hydrophobic residues of the 
fine-stranded globular protein gels, and this could happen 
independently of the extension of the hydrophilic area of the 
protein matrix (Schobert and Tschesche, 1978).
The gels behavior at low (gastric) or neutral (intestinal) 
pH influences the rate of peptide release (Flores and Kong et 
al., 2017). This process take place essentially by decreasing 
protein-protein interactions and up taking water, which pro-
motes the diffusion of peptides outside the gel (Peppas and 
Kavimandan, 2006).Thus, antihypertensive peptides in food 
matrices can be entrapped into protein or polysaccharides 
gels with the required properties to be released in the ade-
quate place throughout the human gastrointestinal tract.
Ten Have et al., (2015) reported that the portal bioa-
vailability of the antihypertensive peptides XPP, is prolonged 
if they are embedded in a protein matrix, while in a whole-
macronutrients matrix the peptides are more available but 
at a low percentage. The sequence XPP have been reported 
for the antihypertensive peptides IPP and VPP (Gleeson et al., 
2017; Rutella et al., 2016). Ten Have et al., (2015) claim that 
the protein matrix improves the bioavailability by prolonging 
gut absorption due to a delayed stomach emptying. Howe-
ver, other factors could decrease the release of peptides from 
the food matrix during gastric digestion i.e., hydrophobic 
interactions (Mandalari et al., 2014). Thus, we consider that 
these findings highlights that antihypertensive peptides can 
be bioaccessible when they are ingested in food matrices as 
part of the dietary treatment and this encourages the design 
of food matrices for functional foods with antihypertensive 
properties.
CONCLUSIONS
Antihypertensive peptides have not been capitalized 
as an adjunct in the treatment of hypertension. The design of 
food matrices with the capability to deliver antihypertensive 
peptides at intestinal level is an essential step to develop 
functional food products that ensures the bioaccessibility 
and/or bioavailability of these functional compounds. Mo-
reover, when food matrices are designed, it is encouraged 
to test them in order to verify their efficacy in vivo, preferen-
tially in well-designed clinical trials. Finally, we believe that 
independently of the food technology approaches used to 
design food matrices for the delivery of antihypertensive 
peptides in functional foods, the approaches must take into 
account the available food producers’ technologies, scientific 
knowledge, and mainly, the food preferences of the target 
population (patients). 
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